MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Pulmatrix Inc

Gesloten

6.49 -2.11

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.46

Max

6.6

Belangrijke statistieken

By Trading Economics

Inkomsten

178K

-1.8M

EPS

-0.495

Winstmarge

-60,266.667

Werknemers

2

EBITDA

144K

-1.8M

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.4M

25M

Vorige openingsprijs

8.6

Vorige sluitingsprijs

6.49

Pulmatrix Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jul 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Marktinformatie

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Marktinformatie

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Acquisities, Fusies, Overnames

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Acquisities, Fusies, Overnames

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Marktinformatie

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus -2-

4 jul 2025, 12:30 UTC

Marktinformatie

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

4 jul 2025, 12:15 UTC

Marktinformatie

Targeted Tariffs Would Likely Support Dollar -- Market Talk

4 jul 2025, 12:13 UTC

Marktinformatie

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

4 jul 2025, 12:02 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Pulmatrix Inc Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.